Decreases phosphorylation and increase YAP activities have been implicated in resistance to a number of cancer drugs (20, 21) including the first- and second-generation EGFR-TKIs (22), and treatment of lung cancer with growth factor (vascular endothelial growth factor (VEGF) and YAP) inhibitors provided promising results in previous studies (3, 23). The gene discussed is EGFR; the disease is cancer.